Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)

OTHER4 trials

Sponsors

Ocuphire Pharma, Inc.

Conditions

Decrease in Night VisionDilationDisturbance; Vision, LossMydriasisNight Vision ComplaintsOcular HypertensionOpen Angle Glaucoma

Phase 2

The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances

CompletedNCT01703559

Ocuphire Pharma, Inc.Decrease in Night Vision, Disturbance; Vision, Loss, Night Vision Complaints

Start: 2011-09-09End: 2012-04-30Updated: 2019-08-01

Safety and Efficacy of Ophthalmic Phentolamine Mesylate in Glaucoma

CompletedNCT03960866

Ocuphire Pharma, Inc.Ocular Hypertension, Open Angle Glaucoma

Start: 2019-05-28End: 2019-09-11Updated: 2023-09-13

Single Dose Study of Phentolamine Mesylate Eye Drops in Patients With Severe Night Vision Disturbances

CompletedNCT04004507

Ocuphire Pharma, Inc.Decrease in Night Vision, Disturbance; Vision, Loss

Start: 2007-08-31End: 2008-02-29Updated: 2024-02-15

Safety and Efficacy of Ophthalmic Phentolamine Mesylate to Reverse Pharmacologically Induced Mydriasis

CompletedNCT04024891

Ocuphire Pharma, Inc.Dilation, Mydriasis

Start: 2019-08-13End: 2019-09-17Updated: 2023-08-29

Related Papers

A randomized phase 2 clinical trial of phentolamine mesylate eye drops in patients with severe night vision disturbances.

2022-10-083 citations